• Topical steroids

Olux-e Generic Name & Formulations

General Description

Clobetasol propionate 0.05%; emulsion aerosol foam.

Pharmacological Class


How Supplied

Foam—50g, 100g


Olux-e Indications


Corticosteroid-responsive dermatoses.

Olux-e Dosage and Administration


≥12yrs: apply thin layer to affected area(s) twice daily (AM & PM); max 50g/week or 21 capfuls/week and 2 consecutive week's treatment per course. Discontinue when control is achieved. Wash hands after application. Do not occlude.


<12yrs: not recommended.

Olux-e Contraindications

Not Applicable

Olux-e Boxed Warnings

Not Applicable

Olux-e Warnings/Precautions


Not for oral, ophthalmic, or intravaginal use. Avoid use on face, axillae, groin, or other intertriginous areas. Do not use for diaper dermatitis or on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, reduce dose, or substitute with less potent corticosteroid if occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Treat infection if present; discontinue if infection persists or worsens. Avoid abrupt cessation in chronic use. Reevaluate periodically. Product is flammable. Pregnancy. Nursing mothers.

Olux-e Pharmacokinetics

See Literature

Olux-e Interactions

Not Applicable

Olux-e Adverse Reactions

Adverse Reactions

Burning, stinging, pruritus, erythema, skin atrophy, folliculitis, dermal cracking and fissuring, telangiectasia, striae; allergic contact dermatitis (discontinue if irritation occurs), HPA axis suppression (esp. in children); rare: Cushing's syndrome, hyperglycemia.

Olux-e Clinical Trials

See Literature

Olux-e Note

Not Applicable

Olux-e Patient Counseling

See Literature